Oncolytic virotherapy – Forging its place in the immunomodulatory paradigm for Multiple Myeloma

Joselle Cook, Aldo A. Acosta-Medina, Kah Whye Peng, Martha Lacy, Stephen Russell

Research output: Contribution to journalArticlepeer-review


The treatment focus for multiple myeloma (MM) has recently pivoted towards immune modulating strategies, with T-cell redirection therapies currently at the forefront of drug development. Yet, despite this revolution in treatment, MM remains without a sustainable cure. At the same time, tremendous advancement has been made in recombinant and gene editing techniques for oncolytic viruses (OV), which have increased their tumor specificity, improved safety, and enhanced the oncolytic and immunostimulatory potential. These breakthrough developments in oncolytic virotherapy have opened new avenues for OVs to be used in combination with other immune-based therapies such as checkpoint inhibitors, chimeric antigen receptor T-cells (CAR-T) and bispecific T-cell engagers. In this review, the authors place the spotlight on systemic oncolytic virotherapy as an adaptable immunotherapeutic for MM, highlight the unique mechanism of OVs in activating the immune-suppressive marrow microenvironment, and lastly showcase the OV platforms and the promising combination strategies in the pipeline for MM.

Original languageEnglish (US)
Article number100473
JournalCancer Treatment and Research Communications
StatePublished - Jan 2021


  • Immunomodulation
  • Multiple Myeloma
  • Oncolytic virus
  • Virotherapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Oncolytic virotherapy – Forging its place in the immunomodulatory paradigm for Multiple Myeloma'. Together they form a unique fingerprint.

Cite this